<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1946">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03058965</url>
  </required_header>
  <id_info>
    <org_study_id>[18F]MNI-958</org_study_id>
    <nct_id>NCT03058965</nct_id>
  </id_info>
  <brief_title>Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain</brief_title>
  <official_title>Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Probable Alzheimer's Disease or Progressive Supranuclear Palsy Compared With Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Molecular NeuroImaging</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Molecular NeuroImaging</source>
  <brief_summary>
    <textblock>
      The overall goal of this imaging trial is to evaluate [18F]MNI-958, a tau targeted PET&#xD;
      radioligand, in individuals with Alzheimer's disease (AD), Progressive Supranuclear Palsy&#xD;
      (PSP), and healthy volunteers (HV).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 29, 2016</start_date>
  <completion_date type="Actual">May 11, 2018</completion_date>
  <primary_completion_date type="Actual">May 11, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tracer uptake will be evaluated in regions of interest for analysis of regional [18F]MNI-958 binding/uptake and expressed in SUV by using established methods for normalization for 3 AD, 3 PSP, and 3 HV subjects.</measure>
    <time_frame>1 year</time_frame>
    <description>Descriptive statistics will be applied to describe the tau deposition by region as measured by [18F]MNI-958.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Alzheimer Disease</condition>
  <condition>Healthy Volunteers</condition>
  <condition>Progressive Supranuclear Palsy</condition>
  <arm_group>
    <arm_group_label>[18F]MNI-958</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To evaluate [18F]MNI-958, a tau targeted PET radioligand.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]MNI-958</intervention_name>
    <description>Subjects will undergo PET imaging using [18F]MNI-958, a PET radioligand for imaging tau.</description>
    <arm_group_label>[18F]MNI-958</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]Florbetapir</intervention_name>
    <description>Subjects with Alzheimer's disease will receive a [18F]florbetapir scan to compare distribution of tau in the brain compared to that of [18F]MNI-958.</description>
    <arm_group_label>[18F]MNI-958</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DaTscan</intervention_name>
    <description>DaTscan SPECT imaging will be completed in those PSP subjects who have not previously had DATScan imaging as part of the screening procedures.</description>
    <arm_group_label>[18F]MNI-958</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:&#xD;
&#xD;
          -  Written informed consent must be obtained before any assessment is performed.&#xD;
&#xD;
          -  Female subjects must be documented by medical records or physician's note to be either&#xD;
             surgically sterile (by means of hysterectomy, bilateral oophorectomy, or tubal&#xD;
             ligation) or post-menopausal for at least 1 year or, if they are of child-bearing&#xD;
             potential, must commit to use a barrier contraception method for the duration of the&#xD;
             study.&#xD;
&#xD;
          -  Male subjects and their partners of childbearing potential must commit to the use of&#xD;
             two methods of contraception, one of which is a barrier method for male subjects for&#xD;
             the study duration.&#xD;
&#xD;
          -  Male subjects must not donate sperm for the study duration.&#xD;
&#xD;
          -  Willing and able to cooperate with study procedures&#xD;
&#xD;
        Inclusion Criteria for Healthy Volunteer Subjects:&#xD;
&#xD;
          -  Males and females aged ≥50 years. Healthy with no clinically relevant finding on&#xD;
             physical examination at screening and upon reporting for the [18F]MNI-958 imaging&#xD;
             visit.&#xD;
&#xD;
          -  No cognitive impairment from neuropsychological battery as judged by the investigator&#xD;
&#xD;
          -  Have screening [18F]florbetapir PET imaging demonstrating no significant amyloid&#xD;
             binding based on qualitative analysis (visual read).&#xD;
&#xD;
          -  No family history of Alzheimer's disease or neurological disease associated with&#xD;
             dementia&#xD;
&#xD;
          -  Have a CDR score=0&#xD;
&#xD;
        Inclusion Criteria for subjects with a diagnosis of probable Alzheimer's disease (AD):&#xD;
&#xD;
          -  Males and females aged 50 to 90 years.&#xD;
&#xD;
          -  Have probable Alzheimer's disease, based on the NINCDS/ADRDA and DSM-IV criteria.&#xD;
&#xD;
          -  Have a CDR score of 0.5 or greater at screening.&#xD;
&#xD;
          -  Have an MMSE score ≤ 28.&#xD;
&#xD;
          -  Have screening or prior (in the last 12 months) [18F]florbetapir PET imaging&#xD;
             demonstrating amyloid binding based on qualitative (visual read)&#xD;
&#xD;
          -  A brain MRI that supports a diagnosis of AD, with no evidence of focal disease to&#xD;
             account for dementia or MRI exclusion criteria.&#xD;
&#xD;
          -  Medications taken for symptomatic treatment of AD must be maintained on a stable&#xD;
             dosage regimen for at least 30 days before the screening visit.&#xD;
&#xD;
          -  Signed and dated written informed consent obtained from the subject and the subject's&#xD;
             legally authorized representative or caregiver (if applicable).&#xD;
&#xD;
          -  The subject has an appropriate caregiver capable of accompanying subject, if&#xD;
             necessary.&#xD;
&#xD;
        Inclusion Criteria for subjects with a diagnosis of probable Progressive Suprnuclear Palsy&#xD;
        (PSP)&#xD;
&#xD;
          -  Males and females aged 50 to 90 years.&#xD;
&#xD;
          -  Has a clinical diagnosis of PSP based on the NINDS and Society for PSP criteria&#xD;
             (Litvan, et al 1996).&#xD;
&#xD;
          -  Have screening or prior DaTscan SPECT imaging demonstrating evidence of dopamine&#xD;
             transporter deficit based on visual read.&#xD;
&#xD;
          -  A brain MRI that supports a diagnosis of PSP, with no other evidence of significant&#xD;
             neurologic pathology&#xD;
&#xD;
          -  Medications taken for symptomatic treatment of PSP must be maintained on a stable&#xD;
             dosage regimen for at least 30 days before screening visit.&#xD;
&#xD;
          -  Signed and dated written informed consent obtained from the subject and the subject's&#xD;
             legally authorized representative or caregiver (if applicable).&#xD;
&#xD;
          -  The subject has an appropriate caregiver capable of accompanying subject, if&#xD;
             necessary.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or prior history of any alcohol or drug abuse.&#xD;
&#xD;
          -  Laboratory tests with clinically significant abnormalities and/or clinically&#xD;
             significant unstable medical illness.&#xD;
&#xD;
          -  Subject has received an investigational drug or device within 30 days of screening&#xD;
&#xD;
          -  Prior participation in other research protocols or clinical care in the last year in&#xD;
             addition to the radiation exposure expected from participation in this clinical study,&#xD;
             such that radiation exposure exceeds the effective dose of 50 mSv, which would be&#xD;
             above the acceptable annual limit established by the US Federal Guidelines&#xD;
&#xD;
          -  Pregnancy, lactating or breastfeeding.&#xD;
&#xD;
          -  Evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal,&#xD;
             hematological, neoplastic, endocrine, alternative neurological, immunodeficiency,&#xD;
             pulmonary, or other disorder or disease.&#xD;
&#xD;
          -  Unsuitable veins for repeated venipuncture.&#xD;
&#xD;
          -  MRI exclusion criteria include: evidence of cerebrovascular disease (more than two&#xD;
             lacunar infarcts, any territorial infarct &gt;1cm3, or deep white matter abnormality&#xD;
             corresponding to an overall Fazekas scale of 3 with at least one confluent&#xD;
             hyperintense lesion on the FLAIR sequence that is ≥20 mm in any dimension), infectious&#xD;
             disease, space-occupying lesions, normal pressure hydrocephalus or any other&#xD;
             abnormalities associated with CNS disease.&#xD;
&#xD;
          -  Implants such as implanted cardiac pacemakers or defibrillators, insulin pumps,&#xD;
             cochlear implants, metallic ocular foreign body, implanted neural stimulators, CNS&#xD;
             aneurysm clips and other medical implants that have not been certified for MRI, or&#xD;
             history of claustrophobia in MRI.&#xD;
&#xD;
        Exclusion Criteria for Subjects with Probable AD:&#xD;
&#xD;
          -  Has received treatment that targeted amyloid-β or tau within the last 3 months.&#xD;
&#xD;
        Exclusion Criteria for Subjects with Probable PSP:&#xD;
&#xD;
          -  Ongoing treatment with methylphenidate, bupropion, modafinil, metoclopramide, alpha&#xD;
             methyldopa, reserpine, or amphetamine derivative.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Molecular NeuroImaging, LLC</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>January 12, 2017</study_first_submitted>
  <study_first_submitted_qc>February 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>March 21, 2019</last_update_submitted>
  <last_update_submitted_qc>March 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AD</keyword>
  <keyword>HV</keyword>
  <keyword>PSP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

